Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



## InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9969)

## VOLUNTARY ANNOUNCEMENT ON ADOPTION OF OFFICIAL SECOND AMENDED AND RESTATED

## MEMORANDUM AND ARTICLES OF ASSOCIATION

This is a voluntary announcement made by InnoCare Pharma Limited (the "Company"). Reference is made to (i) the circular of the Company dated 18 May 2022 and (ii) the announcement of the Company dated 11 May 2022 in connection with the proposed amendments to (a) the current amended and restated memorandum of association and articles of association of the Company, and (b) the RMB Share Issue M&A (together, the "Relevant Publications"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings ascribed to them in the Relevant Publications.

The board of directors of the Company wishes to inform the Company's shareholders that, as of the date of this announcement, being also the date of the 2021 AGM, the RMB Share Issue is still in progress. Therefore, in accordance with the Relevant Publications, the version of the Second Amended and Restated Memorandum and Articles of Association incorporating and consolidating all the Proposed Amendments to the Current M&A will be adopted with immediate effect and referred to as the official Second Amended and Restated Memorandum and Articles of Association.

By Order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 21 June 2022

As at the date of this announcement, the Board of Directors comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie, Mr. Shan Fu and Mr. Ming Jin as non-executive Directors, and Dr. Zemin Zhang, Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.